Corporate ActionMay 5, 2026, 04:13 PM
Dianthus Raises $719M in March 2026 Public Offering
AI Summary
Dianthus Therapeutics reported a net loss of $40.8 million for the first quarter of 2026, an increase from $29.5 million in the prior year, primarily due to higher research and development and general and administrative expenses. However, the company significantly bolstered its financial position by raising approximately $719.0 million in gross proceeds from a public offering in March 2026. This financing activity led to a substantial increase in cash and cash equivalents to $627.7 million as of March 31, 2026, and is expected to fund operations for at least twelve months.
Key Highlights
- March 2026 Public Offering raised approximately $719.0 million in gross proceeds.
- Cash and cash equivalents increased to $627.7 million as of March 31, 2026, from $51.1 million on Dec 31, 2025.
- Net loss for Q1 2026 was $40.8 million, compared to $29.5 million for Q1 2025.
- Net loss per share was $(0.85) for Q1 2026, compared to $(0.82) for Q1 2025.
- Research and development expenses rose to $34.5 million in Q1 2026 from $27.0 million in Q1 2025.
- General and administrative expenses increased to $12.5 million in Q1 2026 from $7.3 million in Q1 2025.
- Total stockholders’ equity increased to $1.20 billion as of March 31, 2026, from $493.4 million on Dec 31, 2025.
- Company expects existing cash to fund operations for at least twelve months.